Suzhou Ribo

Boehringer bets $2B in biobucks to unlock siRNA targets for NASH treatments
Fierce Biotech
Wed, 01/3/24 - 09:40 am
Boehringer Ingelheim
biobucks
NASH
siRNA
Suzhou Ribo
Ribocure